

**Timor-Leste**

**VACCINE SUPPORT**

**This Decision Letter sets out the Programme Terms of a Programme**

<b>1. Country: Timor-Leste</b>				
<b>2. Grant Number: 1215-TLS-04c-X</b>				
<b>3. Date of Decision Letter: 23 September 2014</b>				
<b>4. Date of the Partnership Framework Agreement: 24 January 2014</b>				
<b>5. Programme Title: NVS, Pentavalent Routine</b>				
<b>6. Vaccine type: Pentavalent</b>				
<b>7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID</b>				
<b>8. Programme Duration<sup>1</sup>: 2012 - 2015</b>				
<b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>				
	2012-2013	2014	2015	Total <sup>2</sup>
Programme Budget (US\$)	US\$601,949 <sup>3</sup>	US\$56,000	US\$102,000	US\$759,949
<b>10. Vaccine Introduction Grant: The Vaccine Introduction Grant (VIG) was already awarded for the introduction of Pentavalent Vaccine in 2012.</b>				

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>3</sup> This is the consolidated amount for all previous years.

**11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>4</sup>**

Type of supplies to be purchased with GAVI funds in each year	2014	2015
Number of Pentavalent vaccines doses	31,500	59,000
Number of AD syringes	9,500	44,800
Number of re-constitution syringes		0
Number of safety boxes	125	500
Annual Amounts (US\$)	US\$56,000	US\$102,000

**12. Procurement agency:** UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.

**13. Self-procurement:** Not applicable.


**14. Co-financing obligations: Reference code: 1215-TLS-04c-X-C.** According to the Co-Financing Policy, the Country falls within the group Graduating. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2014	2015
Number of vaccine doses	19,500	63,500
Number of AD syringes	5,800	47,500
Number of re-constitution syringes		0
Number of safety boxes	75	550
Value of vaccine doses (US\$)	US\$30,224	US\$100,733
Total Co-Financing Payments (US\$) (including freight)	US\$34,000	US\$108,000

<sup>4</sup> This is the amount that GAVI has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

<b>15. Operational support for campaigns:</b> Not applicable		
	2014	2015
Grant amount (US\$)		
<b>16. Additional documents to be delivered for future disbursements:</b>		
Reports, documents and other deliverables	Due dates	
Annual Progress Report or equivalent	To be agreed with Gavi Secretariat	
<b>17. Financial Clarifications:</b> Not applicable.		
<b>18. Other conditions:</b> Not applicable.		

Signed by,



**On behalf of the GAVI Alliance**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
23 September 2014

## Timor-Leste

### Health Systems Strengthening

#### This Decision Letter sets out the Programme Terms of a Programme.

1. <b>Country:</b> Timor-Leste
2. <b>Programme Payment Grant number:</b> 1418-TLS-10d-Y
3. <b>Performance Payment Grant number:</b> N/A
4. <b>Date of Decision Letter:</b> 23 September 2014
5. <b>Date of the Partnership Framework Agreement:</b> 24 January 2014
6. <b>Programme Title:</b> Health Systems Strengthening (HSS)
<p>7. <b>HSS terms:</b></p> <p>The ultimate aim of HSS support is to ensure increased and sustained immunisation coverage through addressing health systems barriers in Country, as specified in:</p> <ul style="list-style-type: none"> <li>• The relevant GAVI HSS guidelines – please contact your SCM at <a href="mailto:athomson@gavi.org">athomson@gavi.org</a> for the guidelines.</li> <li>• The relevant GAVI HSS application form - please contact your SCM at <a href="mailto:athomson@gavi.org">athomson@gavi.org</a> for the form.</li> <li>• Country's approved grant proposal and any responses to the HSS IRC's request for clarifications.</li> </ul>
<p>8. <b>Application of Performance Based Funding (PBF):</b></p> <p>Does PBF apply:</p> <p>YES <input type="checkbox"/></p> <p>NO <input checked="" type="checkbox"/></p> <p><b>If the answer is YES, please refer to section 8 outlining performance grant details.</b></p>
<p>9. <b>GAVI Performance Based Funding</b></p> <p>The HSS cash support shall be subject to GAVI's performance-based funding (PBF). Under this, the HSS support will be split into two payments: the programmed payment (based on implementation of the approved HSS grant) and the performance-based payment (based on improvements in immunisation outcomes). This means that in the first year, Country will receive 100% of the approved ceiling, or programme budget if different (the initial Annual Amount), as an upfront investment. After the first year, countries will receive 80% of the ceiling, or programme budget if different, based on implementation of the grant, and additional payments will be based on performance on immunisation outcome indicators. Note that countries whose total grant budget would fall below US\$3 million are exempt from this 80% rule.</p> <p>Country will have the opportunity to receive payments beyond the programme budget amount, for exceptional performance on the same immunisation outcomes. The maximum programmed payment plus performance payment may be up to 150% of the country ceiling.</p> <p><u>Performance payments for a given year will be made the following year, based on performance of the indicators listed and data verification.</u></p> <p><b>GAVI Calculation of Performance Payments for 2013 achievements – TOTALS:</b></p> <p>Given that Country's DTP3 coverage was <b>below 90%</b> at baseline, which is defined as the year prior to the first year of HSS</p>

grant implementation, and based on WHO/UNICEF estimates, Country will be rewarded for improving coverage with:

- \$30 per additional child immunised with DTP3, if DTP3 coverage increases and
- \$30 per additional child immunised with first dose of measles containing vaccine, if measles coverage increases.

Reported DTP3 coverage (WUENIC) at baseline*	Countries with DTP3 coverage < 90% at baseline				TOTAL Performance Payment to the country
	DTP3 performance payment	Amount of DTP3 performance payment (US\$)	MCV1 performance payment	Amount of MCV1 performance payment (US\$)	

10. Programme Duration<sup>5</sup>: 2014 to 2018

11. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement, if applicable):

	2014	2015	2016	2017	2018	Total <sup>6</sup>
Programme Budget (US\$)	US\$534,164	US\$334,349	US\$566,385	US\$805,192	US\$758,557	US\$2,998,647

12. Annual Amounts (subject to the terms of the Partnership Framework Agreement):

The following disbursements are subject to the conditions set out in sections 6, 10, 11 and 12:

Programme Year	2014	2015
Annual Amount (\$US)	534,164	US\$334,349
Performance Payment (\$US)		Not applicable

13. Financial Clarifications: The Country shall provide the following clarifications to GAVI<sup>7</sup>:

If the bank account information most recently provided to GAVI has changed or changes prior to disbursement, the country will need to complete a bank account information form. Please contact [gavihss@gavi.org](mailto:gavihss@gavi.org) for the form.

<sup>5</sup> This is the entire duration of the programme.

<sup>6</sup> This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>7</sup> Failure to provide the financial clarifications requested may result in GAVI withholding further disbursements

**14. Documents to be delivered for future HSS cash disbursements:**

The Country shall deliver the following documents by the specified due dates as part of the conditions for approval and disbursements of the future Annual Amounts.

Reports, documents and other deliverables	Due dates
Annual Progress Reports (APRs), or equivalent. The APRs, or equivalent, shall provide detail on the progress against milestones and targets against baseline data for indicators identified in the proposal. The APRs, or equivalent, should also include a financial report on the use of GAVI support for HSS (which could include a joint pooled funding arrangement report, if appropriate).	To be agreed with GAVI Secretariat
Interim unaudited financial reports. Unless stated otherwise in the existing Aide Memoire between GAVI and the Country, the Country shall deliver interim unaudited financial reports on the HSS cash support no later than 45 days after the end of each 6-month reporting period (15 February for the period covering 1 July – 31 December and 15 August for the period covering 1 January – 30 June). Failure to submit timely reports may affect future funding.	15 February and 15 August

**15. Other conditions: The following terms and conditions shall apply to HSS support.**

Cash disbursed under HSS support may not be used to meet GAVI's requirements to co-finance vaccine purchases.


In case the Country wishes to alter the disbursement schedule over the course of the HSS programme, this must be highlighted and justified in the APR, or equivalent, and will be subject to GAVI approval. It is essential that Country's Health Sector Coordination Committee (or its equivalent) be involved with this process both in its technical process function and its support during implementation and monitoring of the HSS programme proposal. Utilisation of GAVI support stated in this letter will be subject to performance monitoring.

**16. Other conditions: The following terms and conditions shall apply to performance payments.**

The performance payments under the performance-based funding shall be used solely for activities to be implemented in the country's health sector.

Neither programme nor performance payments may be used to purchase vaccines or meet GAVI's requirements to co-finance vaccine purchases, and shall not be used to pay any taxes, customs, duties, toll or other charges imposed on the importation of vaccines and related supplies.

Signed by,



**On behalf of the GAVI Alliance**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
23 September 2014